Zomedica Corp. · OTC:ZOMDF
Zomedica — Investor Presentation (February 2024)
36 slides from Zomedica's investor presentation, February 2024
Slide 1: Zomedica February 2024
ZOMEDICA February 2024
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Advancing Animal Health & Veterinarian Success
Advancing Animal Health & Veterinarian Success 3
Slide 4: Zomedica's Mission
Zomedica’s Mission Bring innovative diagnostic and therapeutic technology to Veterinarians to improve the quality of care for the pet, the satisfaction of the pet parent, and the workflow, cash flow and profitability of the practice 4
Slide 5: Zomedica At A Glance
Zomedica At A Glance ProvenTrack Record of $2.5B Total Annual Recurring Revenue Addressable Market1 Financial Performance ~29% Therapeutic Devices FY23 Revenue Growth2 Therapeutic Diagnostics Devices ~250% Diagnostics FY23 YoY Revenue Growth2 Addressing two of the fastest growing segments of Animal
Slide 6: Key Takeaways
DeliveringOutstanding ResultsThrough Focused Execution Significant market opportunity to address critical animal health needs Existing portfolio comprised of truly innovative technology platforms Global commercial channel in place to drive widespread adoption Key Takeaways Opportunities to expand ou
Slide 7: Trends in Animal Health Have Set the Stage for a Huge Opportunity
Trends in Animal Health Have Set the Stage for a Huge Opportunity Pet Ownership is Increasing >23M U.S households who adopted a pet during the pandemic4 Pet Owners Are Getting Younger ~50% % Gen-Z U.S dog-owning households with one or more dogs under the age of two5 $62 B The Human-Animal Bond is In
Slide 8: Our Portfolio is Well-Positioned to Address Critical Animal Health Needs
Our Portfolio is Well-Positioned to Address Critical Animal Health Needs Therapeutic Devices ZOM•Dx Accelerate Healing, Reduce Pain Cutting-Edge Diagnostic Technology By Delivering Innovation to Veterinarians and Pet Parents, We Seek to Improve: 1 The quality of 2The satisfaction 3 Veterinarian 4 Ve
Slide 9: Zomedica Has the Opportunity to Service A Multi-Billion Dollar Market
Zomedica Has the Opportunity to Service A Multi-Billion Dollar Market U.S. Customer Base U.S. Total Annual Serviceable Market 4,450 Recurring Revenue Opportunities Equine or Mixed Practices $500 M $1,500 M $290 M $150 M TRUVIEW TRUFORMA Assisi PulseVet $40 M VetGuardian = $2.5 B Total Annual Market1
Slide 10: Zomedica Has Driven Sustained Growth With a Strong Financial Profile
Zomedica Has Driven Sustained GrowthWith a Strong Financial Profile Total Revenue ($000’s) >$7,0002 $6,347 $6,157 $5,482 $6,020 Financial Strength $4,776 $4,081 $3,751 $4,246 >32% FY 2023 YoY Revenue Growth2 ~69% Gross Margins 3 $14 $16 $23 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23
Slide 11: Delivering Product Innovation
Delivering Product Innovation 11
Slide 12: Therapeutic Devices: PulseVet
Total Available Annual Market (US) Therapeutic Devices: PulseVet Recurring Revenue $150 M Capital Revenue $1,000 M The Global Leader in Shock Wave Technology Clinically proven to enhance the quality & speed of healing in various musculoskeletal indications, from ligament and tendon injuries to osteo
Slide 13: Therapeutic Devices: Assisi
Therapeutic Devices:Assisi Total Available Annual Market (US) $290M Assisi tPEMF therapy Complements PulseVet Shock Wave therapy at Home Assisi Loop® & Assisi Loop Lounge® Recently Launched Line Extensions • Sold for pain and inflammation from OA, and • DentaLoop® device indicated for gum disease an
Slide 14: ZOM•Dx: TRUVIEW
ZOM•Dx:TRUVIEW Total Available Annual Market (US) $500 M Digital Cytology Platform & Pathology Services Innovative digital imaging system with LiquiView liquid lens optics provide best-in- class visualization with TRUprep fully automated slide prep • First-in-class automated slide preparation • Redu
Slide 15: ZOM•Dx: TRUFORMA
ZOM•Dx:TRUFORMA Total Available Annual Market (US) $1,500 M Reference Lab Accuracy at the Point of Care with TRUFORMA Diagnostic Platform Disposable cartridge preloaded with reagents Timely and accurate results Minimizes sample prep & simplifies workflow Supports practitioner’s ability to diagnose w
Slide 16: ZOM•Dx: VetGuardian
Total Available Market (US) ZOM•Dx:VetGuardian Annual Recurring Revenue $40 M Capital Revenue $465 M Wireless Remote Monitoring System Ensure vulnerable pets are efficiently monitored 24-hour no touch vital signs monitoring capability provides improved care for pet patients, enhanced workflow and ne
Slide 17: Driving Widespread Adoption
Driving Widespread Adoption 17
Slide 18: Sales: Leveraging a Well-Established Commercial Infrastructure to Drive Adoption
Sales: Leveraging a Well-Established Commercial Infrastructure to DriveAdoption Direct Salesforce Distribution Networks U.S. Japan Europe Australia Middle East Led by Established U.S. Direct Salesforce Supplementing U.S. Efforts With Distribution Network • Selling Core Products: PulseVet, TRUFORMA,
Slide 19: Sales: Improved Focus of Direct Sales Channel to Drive Incremental Gains
Sales: Improved Focus of Direct Sales Channel to Drive Incremental Gains Targeting key Veterinarian practices by segment Veterinary Channel Using distribution relationships to better access new customers PulseVet: Leveraging the exceptional acceptance in the equine market to drive adoption in small
Slide 20: Marketing: Leveraging a Unique Omnichannel Strategy to Drive Adoption
Marketing: Leveraging a Unique Omnichannel Strategy to DriveAdoption Leading with Multi-Channel Sales Focus Market Development Is The Key Internal Sales Focusing on increasing awareness and understanding Force of Zomedica’s portfolio by: U.S. and Int’l #1 Maximizing Customer Education Initiatives eC
Slide 21: Winning With Science & Data
Winning With Science & Data 21
Slide 22: R&D: Core Technology Capabilities Set the Stage for Continued Innovation
R&D: CoreTechnology Capabilities Set the Stage for Continued Innovation TRUVIEW Product Line Launch VetGuardian Product Line Launch Assisi Product Line Launch PulseVet Product Line Launch TRUFORMA Assay Launch Product Line Launch Assay Launch Assay Launch Assay Launch cPL Canine eACTH fT4 Equine eAC
Slide 23: R&D: The Next Phase of Product Innovation to Drive Increased Utilization
R&D:The Next Phase of Product Innovation to Drive Increased Utilization Therapeutic Devices ZOM•Dx New Indications New Assays • PulseVet, Assisi: Supporting clinical studies • TRUFORMA: Continue to add new high-value assays to identify new technology applications • Focused on reproductive, cardiac,
Slide 24: myZomedica
R&D: Supporting Improved Pet CareThrough DigitalTechnology Solutions myZomedica ® A Hub for Clinical & Customer Experiences Allows our veterinary partners to engage with us beyond just test results • A stage for delivering clinical decision support • An eCommerce platform for streamlining the reorde
Slide 25: R&D: The Future of Zomedica's Information Technology Offerings
R&D:The Future of Zomedica’s Information Technology Offerings Diagnostic Systems Therapeutic Devices Device-to-Cloud Capabilities Continue to leverage Internet of Things device-to-cloud messaging to support a foundation for AI Clinical Content Delivery Capabilities Continue to expand use of device p
Slide 26: Achieving Operational Efficiencies
Achieving Operational Efficiencies 26
Slide 27: Manufacturing: Best-in-Class Capabilities Across Two U.S. Facilities
Manufacturing: Best-in-ClassCapabilities AcrossTwo U.S. Facilities Zomedica Global Manufacturing & Distribution Center, South Zomedica Global Manufacturing & Distribution Center, North Zomedica Biotechnologies Roswell, GA Plymouth, MN • Established in August, 2022 • Acquired in October, 2023 as part
Slide 28: Manufacturing: Driving Leverage Through Operational Efficiencies
Manufacturing: Driving LeverageThroughOperational Efficiencies Key Enablers of Improving Operational Efficiency Ability to scale Roswell by 5x to meet future growth targets Through prior investments, Zomedica Full integration of Qorvo Biotechnologies’ R&D and manufacturing facility is positioned to
Slide 29: Scaling Through Acquisition
Scaling Through Acquisition 29
Slide 30: Zomedica's Long Term Growth Strategy
Zomedica’sLong Term Growth Strategy Over the past three years, Zomedica has been driving a three-part growth strategy 1 Acquire high-potential, high-growth businesses that benefit the patient, 2 Integrate these businesses efficiently 3 Leverage Zomedica’s commercial to leverage best-in-class capabil
Slide 31: Innovation Worthy of Investment
Innovation Worthy of Investment Track record of identifying and efficiently acquiring highly differentiated, high potential technologies that elevate the standard of care in Animal Health • We’ve created a best of the best portfolio with strong growth, high margins, and huge TAM’s • Many are still i
Slide 32: Producing Compelling Results
Producing Compelling Results 32
Slide 33: Future Growth Driven by Continued Commercial Execution
Future Growth Driven by Continued Commercial Execution FY 2024 Revenue Guidance Range Bridge ($M) 9 Key Growth Drivers +40% • Momentum from a bigger, more mature salesforce +$4 $35 YoY Growth at High-End • Further penetrating non-equine veterinarians • Select international market expansions $31 +24%
Slide 34: Zomedica Has Delivered Compelling Financial Performance
Zomedica Has DeliveredCompelling Financial Performance Increased Revenue in 2023 ($M) Maintained Strong Adj. Gross Margins in 2023 8 $25.0* $18.9 >+32% 70% 70% 70% $4.1 $0.0 2020 2021 2022 2023 1Q'23 2Q'23 3Q'23 Non-GAAP Adj. Cash Burn in 2023 Significant Liquidity Self-Fund’s Execution of Growth St
Slide 35: Q&A
O&A <_— ZOMEDICA
Slide 36: References
References 1. Company estimates 2. Preliminary unaudited 2023 performance as announced on January 17, 2024 3. Gross margin, as reported for 3Q’23 4. The American Society for the Prevention of Cruelty to Animals (ASPCA) 5. IDEXX US Pet Parent Research Study (December 2021) 6. The Human Animal Bond In